I thought this was going to be a good week, as there were some recoveries in
many of my shares, but a 2p drop in OPTI:Optibiotix wiped out all those gains
so I ended up losing £1,899 to extend the deficit between cost and value to
£42,138 and the overall portfolio value dropped to £106,933 and is getting
perilously close to going under £100k.
Blackrock World Gold Fund had a good week, climbing 6% but it is still 3%
down.
DDDD:4D Pharma is one of my largest holdings, so a 6% rise was most welcome,
but they are still 45% down.
Share of the Week was JLP:Jubilee Metals which climbed by 9% which isn't a lot
given they are now 259% up and any change is big compared to my purchase
price.
The only good thing I can say is that the recent drop is less steep than in previous
weeks!
| Weekly Change | |||
| Cash | £52.50 |
+£0 | |
| Portfolio cost | £69,679.47 | +£0 | |
| Portfolio sell value (bid price-commission) | £51,252.66 | (-26.4%) | -£997.84 |
| Potential profits | £4,297.14 | +£153.01 | |
| Yr 7 Dividends | £22.16 | +£0 | |
| Yr 7 Profit from sales | £1,465.26 | +£0 | |
| Yr 7 projected avg monthly profit | £641.30 | (17.5%) | -£71.25 |
| Total Dividends | £1,365.31 | +£0 | |
| Total Profit from sales | £25,589.20 | +£0 | |
| Average monthly cash profit |
£358.85 |
(9.8%) | -£1.12 |
|
(Sold stocks profit + Dividends - Fees / Months) |
|||
| Compound performance | 61% | +0% |
JLP:Jubilee Metals improved potential profits by £153, but OPTI:Optibiotix caused almost £1,000 to come off the total value. Long term performance is still only just below target.
Only just above 12 month low on the performance chart and getting way too close to the injection line for comfort.
The SIPP looks like this after week 306 overall and week 46 of year 6.
| Weekly Change | ||||
| Cash | £244.30 | +£0 | ||
| Portfolio cost | £76,462.89 | +£0 | ||
|
Portfolio sell value (bid price - commission) |
£54,042.63 | (-29.3%) | -£939.68 | |
| Potential profits | £223.36 | +£45.00 | ||
| Yr 6 Dividends | £988.63 | +£0 | ||
| Yr 6 Interest | £0 | +£0 | ||
| Yr 6 Profit from sales | £8,241.18 | +£0 | ||
| Yr 6 projected avg monthly profit | £852.09 | (22.2%) | -£18.94 | |
| Total Dividends | £3,055.71 | +£0 | ||
| Total Interest | £0.20 | +£0 | ||
| Total Profit from sales | £23,700.62 | +£0 | ||
| Average monthly cash profit | £367.50 | (9.6%) | -£1.20 | |
|
(Sold stocks profit + Dividends - Fees / Months) |
||||
| Compound performance | 56% | +0% |
Very little change, with CAML:Central Asia Metals increasing potential profits by £45 and OPTI:Optibiotix undoing all the good in the portfolio to reduce value by £939. Long term performance a bit further behind target than the ISA but still not bad.
Way worst position than for more than 12 months.
The trading account looks like this after week 272 overall and week 12 of year 6.
A rare increase in value thanks to the slight recovery in DDDD:4D Pharma, but still 54% down.
| Weekly Change | |||
| Cash | £259.74 | +£0 | |
| Portfolio cost | £2,374.14 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,082.22 | (-54.4%) | +£37.75 |
| Potential profits | £0.00 | +£0 | |
| Year 6 Dividends | £0.00 | +£0 | |
| Year 6 Profit | £0.00 | +£0 | |
| Yr 6 projected avg monthly profit | £0.00 | (0%) | +£0 |
| Dividends | £60.10 | +£0 | |
| Profit from sales | £937.88 | +£0 | |
| Average monthly cash profit | £15.90 | (8.0%) | -£0.06 |
|
(Sold stocks profit + Dividends - Fees / Months) |
A rare increase in value thanks to the slight recovery in DDDD:4D Pharma, but still 54% down.
Still well below both the injection line and the steeply descending trend line.
That's the last of the holiday catch-up weeks. Need news for both
OPTI:Optibiotix and DDDD:4D Pharma to try and salvage something from this
mess.
No comments:
Post a Comment